HpVac

HpVac is a private company established in 2016 that focuses on developing novel microbiome-based therapies. Its lead compound, HpVac-R13, is designed as a first-line treatment for the prevention and management of asthma, eczema, food allergies, related allergic conditions, as well as inflammatory bowel diseases such as Crohn's disease and ulcerative colitis.